Extracellular proteolysis and cancer: meeting summary and future directions
- PMID: 14559785
Extracellular proteolysis and cancer: meeting summary and future directions
Abstract
The contribution of extracellular proteolysis to processes of tumor invasion and metastasis has been recognized for more than 20 years. However, after millions of dollars and untold hours of investment in preclinical research and the development of broad range inhibitors of MMPs, clinical trials of late-stage tumor patients show no indication that this approach will be successful. In the basic science arena, there have been stunning advancements that illustrate novel biological activities for proteases and that suggest they are key regulators of many physiological and pathological processes. The Proteases and Cancer: Biology and Therapeutics Workshop (held in Bethesda, MD, November 20-22, 2002) was organized by the Division of Cancer Biology, National Cancer Institute (NCI) to identify research areas and directions that will accelerate understanding protease biology and enhance clinical translation. The overall consensus was that protease biology represents fertile ground for advances that will be clinically useful but perhaps not for the reasons or purpose originally thought. Protease-related technologies show particular promise for the detection, prognosis, and prevention of cancer, and for therapeutic purposes in defined situations. Promising areas for further research are identified, and specific recommendations for the development of a consortium to coordinate the efforts of the protease community are made.
Similar articles
-
Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1927-1939. doi: 10.1016/j.bbamcr.2017.06.009. Epub 2017 Jun 19. Biochim Biophys Acta Mol Cell Res. 2017. PMID: 28636874 Review.
-
Biological activity and clinical implications of the matrix metalloproteinases.Anticancer Res. 2008 Mar-Apr;28(2B):1389-97. Anticancer Res. 2008. PMID: 18505085 Review.
-
[Expression of matrix metalloproteinases in patients with malignant tumors].Medicina (Kaunas). 2004;40(12):1143-50. Medicina (Kaunas). 2004. PMID: 15630339 Review. Lithuanian.
-
Development of matrix metalloproteinase inhibitors in cancer therapy.Hematol Oncol Clin North Am. 2002 Oct;16(5):1189-227. doi: 10.1016/s0889-8588(02)00044-8. Hematol Oncol Clin North Am. 2002. PMID: 12512389 Review.
-
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.Science. 2002 Mar 29;295(5564):2387-92. doi: 10.1126/science.1067100. Science. 2002. PMID: 11923519 Review.
Cited by
-
The most likely but largely ignored triggering factor for breast (or all) cancer invasion.J Cancer. 2023 Feb 27;14(4):573-590. doi: 10.7150/jca.82291. eCollection 2023. J Cancer. 2023. PMID: 37057291 Free PMC article.
-
Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection.Biochem Mosc Suppl B Biomed Chem. 2022;16(4):271-291. doi: 10.1134/S1990750822040035. Epub 2022 Nov 16. Biochem Mosc Suppl B Biomed Chem. 2022. PMID: 36407837 Free PMC article.
-
Peptide and protein assays using customizable bio-affinity arrays combined with ambient ionization mass spectrometry.Chem Sci. 2021 Jul 14;12(32):10810-10816. doi: 10.1039/d1sc02311j. eCollection 2021 Aug 18. Chem Sci. 2021. PMID: 34476062 Free PMC article.
-
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.Mol Cell Proteomics. 2014 Nov;13(11):3082-96. doi: 10.1074/mcp.M114.038836. Epub 2014 Jul 23. Mol Cell Proteomics. 2014. PMID: 25056937 Free PMC article.
-
Aminopeptidase activities as prospective urinary biomarkers for bladder cancer.Proteomics Clin Appl. 2014 Jun;8(5-6):317-26. doi: 10.1002/prca.201300118. Epub 2014 Mar 31. Proteomics Clin Appl. 2014. PMID: 24591208 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources